Threshold Pharmaceuticals

Threshold Pharmaceuticals Newswire

Comprehensive Real-Time News Feed for Threshold Pharmaceuticals.

Results 1 - 20 of 109 in Threshold Pharmaceuticals

  1. Insider Buying: Nipun Davar Acquires 3,000 Shares of Threshold Pharmaceuticals StockRead the original story

    Tuesday Oct 14 | AmericanBankingNews.com

    Threshold Pharmaceuticals VP Nipun Davar bought 3,000 shares of the stock on the open market in a transaction dated Monday, October 13th. The shares were purchased at an average price of $2.99 per share, with a total value of $8,970.00.

    Comment?

  2. CTRC-led study lands major FDA grantRead the original story w/Photo

    Monday Oct 6 | Business Journal

    ... companies. Glioblastoma, while devastating, is not common and so is considered an orphan disease. Threshold Pharmaceuticals, the company that developed the drug, is supplying it for the clinical trial. The Dana-Farber Cancer Institute and the ...

    Comment?

  3. Threshold Pharmaceuticals, Inc. (THLD) - Financial and Strategic SWOT ...Read the original story

    Monday Oct 6 | PR-inside.com

    2014-10-06 11:16:29 - New Pharmaceuticals market report from GlobalData: "Threshold Pharmaceuticals, Inc. (THLD) - Financial and Strategic SWOT Analysis Review" This comprehensive SWOT profile of Threshold Pharmaceuticals, Inc. provides you an ...

    Comment?

  4. CTRC researcher receives special $1.62 million orphan disease grant from FDARead the original story w/Photo

    Sunday Oct 5 | Medical News

    ... companies. Glioblastoma, while devastating, is not common and so is considered an orphan disease. Threshold Pharmaceuticals, the company that developed the drug, is supplying it for the clinical trial. Also participating in the study will be ...

    Comment?

  5. Threshold Pharmaceuticals Director Jeffrey W. Bird Sells 238,520 SharesRead the original story

    Friday Oct 3 | AmericanBankingNews.com

    Threshold Pharmaceuticals Director Jeffrey W. Bird unloaded 238,520 shares of Threshold Pharmaceuticals stock on the open market in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $3.77, for a total transaction of $899,220.40.

    Comment?

  6. Threshold Pharmaceuticals major shareholder Hill Ventures Sutter Sells 226,657 SharesRead the original story

    Friday Oct 3 | AmericanBankingNews.com

    Threshold Pharmaceuticals major shareholder Hill Ventures Sutter sold 226,657 shares of the company's stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $3.77, for a total value of $854,496.89.

    Comment?

  7. CTRC doctor wins $1.6 million FDA orphan grant to treat deadly brain tumorsRead the original story w/Photo

    Thursday Oct 2 | EurekAlert!

    ... companies. Glioblastoma, while devastating, is not common and so is considered an orphan disease. Threshold Pharmaceuticals, the company that developed the drug, is supplying it for the clinical trial. Also participating in the study will be ...

    Comment?

  8. Threshold Pharmaceuticals Hits New 52-Week Low at $3.40Read the original story

    Wednesday Oct 1 | AmericanBankingNews.com

    Shares of Threshold Pharmaceuticals hit a new 52-week low on Wednesday , Analyst Ratings Network.com reports. The stock traded as low as $3.40 and last traded at $3.41, with a volume of 471,019 shares changing hands.

    Comment?

  9. Threshold Pharmaceuticals Sees Large Growth in Short InterestRead the original story

    Tuesday Sep 30 | AmericanBankingNews.com

    Threshold Pharmaceuticals saw a large growth in short interest in September. As of September 15th, there was short interest totalling 7,168,240 shares, a growth of 47.0% from the August 29th total of 4,877,832 shares, Analyst RN reports.

    Comment?

  10. Threshold drug moves forward on cancer trial but stock fallsRead the original story w/Photo

    Sep 22, 2014 | Business Journal

    Good news from a late-stage cancer study from Threshold Pharmaceuticals Inc. isn't translating into a boon for its stock. The South San Francisco company said Monday that an independent data monitoring committee - a group that recommends halting or moving forward with clinical trials - said Threshold should continue its trial of the drug TH-302 in patients with soft tissue sarcoma.

    Comment?

  11. Threshold drug moves forward on cancer trial but stock fallsRead the original story w/Photo

    Sep 22, 2014 | Business Journal

    Good news from a late-stage cancer study from Threshold Pharmaceuticals Inc. isn't translating into a boon for its stock. The South San Francisco company said Monday that an independent data monitoring committee - a group that recommends halting or moving forward with clinical trials - said Threshold should continue its trial of the drug TH-302 in patients with soft tissue sarcoma.

    Comment?

  12. Threshold Pharmaceuticals announces TH-302 Phase 3 trial will continueRead the original story

    Sep 22, 2014 | Theflyonthewall.com

    Threshold Pharmaceuticals announces TH-302 Phase 3 trial will continue Threshold Pharmaceuticals announced that the Independent Data Monitoring Committee, or IDMC, has completed the planned interim efficacy and safety analyses of unblinded data for the Company's pivotal Phase 3 clinical trial of TH-302 in combination with doxorubicin versus doxorubicin alone in patients with locally advanced unresectable or metastatic soft tissue sarcoma, or STS. Based on their analyses, which included an assessment of both benefit and risk, the IDMC recommended that the trial should continue as planned to its natural conclusion.

    Comment?

  13. Threshold Pharmaceuticals, Inc. Announces Its Phase 3 Trial Of TH-302 ...Read the original story

    Sep 22, 2014 | BioSpace

    Threshold Pharmaceuticals, Inc. today announced that the Independent Data Monitoring Committee has completed the planned interim efficacy and safety analyses of unblinded data for the Company's pivotal Phase 3 clinical trial of TH-302 in combination with doxorubicin versus doxorubicin alone in patients with locally advanced unresectable or metastatic soft tissue sarcoma . Based on their analyses, which included an assessment of both benefit and risk, the IDMC recommended that the trial should continue as planned to its natural conclusion.

    Comment?

  14. IDMC recommends continuing TH-302 trial, primary efficacy analysis pushed backRead the original story w/Photo

    Sep 22, 2014 | Seeking Alpha

    Based on an interim efficacy and safety analysis, the Independent Data Monitoring Committee recommends the Phase 3 clinical trial of Threshold Pharmaceuticals' TH-302 continue as planned. TH-302 is being evaluated in combination with doxorubicin versus doxorubicin alone in patients with locally advanced unresectable or metastatic soft tissue sarcoma .

    Comment?

  15. Levin Capital Strategies reports 6.9% passive stake in Pinnacle FoodsRead the original story

    Sep 8, 2014 | Theflyonthewall.com

    ... CTI BioPharma (CTIC), up 8.1% after being initiated with an Overweight at Piper Jaffray... Threshold Pharmaceuticals (THLD), up 5% after being initiated with a Buy at Cantor. DOWN AFTER EARNINGS: Pep Boys (PBY), down 6.7% following second quarter ...

    Comment?

  16. CTI BioPharma, Servier enter exclusive PIXUVRI license, collaboration agreementRead the original story

    Sep 8, 2014 | Theflyonthewall.com

    ... CTI BioPharma (CTIC), up 8.1% after being initiated with an Overweight at Piper Jaffray... Threshold Pharmaceuticals (THLD), up 5% after being initiated with a Buy at Cantor. DOWN AFTER EARNINGS: Pep Boys (PBY), down 6.7% following second quarter ...

    Comment?

  17. Pep Boys management to meet with BenchmarkRead the original story

    Sep 8, 2014 | Theflyonthewall.com

    ... CTI BioPharma (CTIC), up 8.1% after being initiated with an Overweight at Piper Jaffray... Threshold Pharmaceuticals (THLD), up 5% after being initiated with a Buy at Cantor. DOWN AFTER EARNINGS: Pep Boys (PBY), down 6.7% following second quarter ...

    Comment?

  18. WhiteWave seen having 50% chance of being acquiredRead the original story

    Sep 11, 2014 | Theflyonthewall.com

    ... CTI BioPharma (CTIC), up 8.1% after being initiated with an Overweight at Piper Jaffray... Threshold Pharmaceuticals (THLD), up 5% after being initiated with a Buy at Cantor. DOWN AFTER EARNINGS: Pep Boys (PBY), down 6.7% following second quarter ...

    Comment?

  19. Natural food makers rise following Annies acquisitionRead the original story

    Sep 9, 2014 | Theflyonthewall.com

    ... CTI BioPharma (CTIC), up 8.1% after being initiated with an Overweight at Piper Jaffray... Threshold Pharmaceuticals (THLD), up 5% after being initiated with a Buy at Cantor. DOWN AFTER EARNINGS: Pep Boys (PBY), down 6.7% following second quarter ...

    Comment?

  20. Threshold adds to yesterday's popRead the original story w/Photo

    Sep 9, 2014 | Seeking Alpha

    Shares of micro cap Threshold Pharmaceuticals gap up on a 7x surge in volume. Prices are up 30% in two days.

    Comment?